HARROW INC

Company Overview

Harrow, Inc. is an eyecare‑focused pharmaceutical company with two reportable segments: Branded (FDA‑approved ophthalmic drugs such as IHEEZO, VEVYE, TRIESENCE, etc.) and ImprimisRx (an ophthalmology‑focused compounding business supplying customized formulations to >10,000 U.S. prescribers). The company uses a hybrid manufacturing model (ImprimisRx finished goods from two NJ facilities, branded products manufactured by third parties globally) and holds minority equity/royalty stakes in clinical‑stage assets (Melt, Surface). Harrow reported a step‑change in 2024 revenue to $199.6M (branded $116.1M; ImprimisRx $83.5M) and narrowed net loss to $17.5M, but faces regulatory (FDA Form 483, voluntary recalls, evolving 503A/503B rules), reimbursement and refinancing risks (Oaktree loan $107.5M maturing Jan 2026 and $75M notes maturing in 2026).

Executive Compensation Practices

Compensation is likely to combine market‑competitive base salaries with annual cash incentives tied to commercialization and commercial metrics (revenue, branded unit uptake, gross margin/EBITDA) and long‑term equity (PSUs, stock‑based awards) tied to strategic milestones and share performance — consistent with specialty drug manufacturers. Company specifics that will shape pay design include heavy commercialization spending (SG&A rose materially for launch hires), milestone‑driven obligations (e.g., TRIESENCE $37M payment), and recent PSUs that generated material payroll tax cash outflows—management disclosed $12.6M YTD financing outflows related to payroll taxes on vested PSUs. Given tight near‑term liquidity and refinancing risk, boards may shift toward performance‑contingent, deferred or equity‑heavy incentives, and include clawback/forfeiture provisions tied to regulatory compliance (FDA findings, recalls) and financial restatements.

Insider Trading Considerations

Insiders at Harrow will often possess material information around product launches, reimbursement/access decisions (pass‑through status, 340B/Medicare dynamics), FDA inspection/remediation outcomes for the NJ 503B facility, and refinancing/loan negotiation status — all of which can materially affect valuation and are likely to drive clustered insider activity. The ImprimisRx business’s cash transactions and direct prescriber relationships can make sales/receivables shifts highly visible internally, so collections improvements or distributor payment extensions have potential to trigger insider buying/selling. Given meaningful debt maturing in early‑to‑mid‑2026 and potential dilution from refinancing or asset sales, expect heightened insider activity tied to debt negotiations and any public updates; standard Section 16 reporting, blackout periods around earnings and pending material regulatory announcements, and potential contractual pay restrictions under financing arrangements should be monitored.